Overview

Vytorin Treating Uncontrolled Lipids (VyTUL) Study (0653A-122)

Status:
Terminated
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
To compare the effectiveness of ezetimibe/simvastatin 10/40 daily to atorvastatin 80 daily in reducing the concentration of ldl-c at endpoint after 6 weeks of treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Atorvastatin
Atorvastatin Calcium
Ezetimibe
Simvastatin